| answer text |
<p>The new Government ‘Vaccines Taskforce’ is working with the BioIndustry Association
Taskforce to review options for increasing the capacity of domestic capability to
manufacture vaccines, in response to COVID-19, including how to support the acceleration
and expand the capacity of the Vaccines Manufacturing and Innovation Centre, so that
it becomes operational earlier than planned and is able to manufacture population
level doses.</p><p>For COVID-19, the type of vaccine manufacturing capacity needed
will be determined by the nature of the vaccine that is developed and the technology
used to produce the vaccines. The scale of facility needed will depend on how potent
the vaccines are, and the productivity of the processes used to produce them.</p><p>This
work is proceeding at pace, with the support of industry and academic partners, to
ensure that we are identifying suitable capacity across different vaccine types, while
those vaccines are still under development.</p>
|
 |
